A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

Trial Details

NCT ID
NCT05873686
Phase
PHASE1
Sponsor
Nuvectis Pharma, Inc.
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • NXP900
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Denver, Colorado, United States|39.73915,-104.9847
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Provide written informed consent.
  • 18 years old or older.
  • Advanced, metastatic, and/or progressive solid tumors for whom there is no authorized or effective therapy available, or for whom such therapies ar…
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →